Industry and Government have a shared goal of attracting inward investment from the life sciences industry as we rebuild the economy and the NHS during the pandemic. EMIG is calling for united action to build on the lessons learned in dealing with the crisis and to leverage the current opportunities available to embed these. This will reinforce and future proof the UK’s position as a world-leading location for life sciences.

The response to the crisis on behalf of the UK institutions
responsible for health care has been unprecedented:

  • The MHRA has played a pivotal role in enabling the ACCORD and RECOVERY trials with all COVID patients enrolled in clinical trials and the research demonstrating the importance of dexamethasone, in time frames previously unimaginable

  • The MHRA, HRA, NICE, NHS England, DHSC and OLS have exceeded expectations and shown what is possible

  • NICE sets the bar globally and is in the process of reviewing its approach (the NICE Methods Review) and has compressed the time taken to issue guidance

  • Changes introduced by NICE can be complemented by NHSE-I. Industry is playing its part through its five-year VPAS commitment to fund all annual medicines bill growth above two percent. The NHS has the opportunity to be an early adopter of innovation without the distraction of cost

Read more

A healthy life sciences sector

Support the rebuild of the UK and NHS following the Covid crisis

A vibrant research community

A large and highly-skilled medtech and manufacturing sector

A concentration of commercial expertise

A flexible and supportive licensing and reimbursement process

A sophisticated and world-beating life sciences support services sector

Support the rebuild of the UK and NHS following the Covid crisis

  • Assist the NHS in getting back to Business As Usual (BAU) using industry expertise in communication, online product information and data
  • Help persuade global decision makers to invest in the UK
  • Ensure innovative medicines reach UK patients
  • Guide the implementation of the VPAS to support NHS affordability
Read more


a vibrant research and development community through advocating for the creation of a Life Sciences Sector Research Collaborative


the building of a large and highly skilled manufacturing sector by pressing for capital investment allowances and tax credits at competitive levels


a concentration of commercial expertise and encourage global pharmaceutical HQs to locate their commercial centres in the UK


patient access to innovative medicines by developing Marketing Authorisation and Health Technology Assessment in parallel, where companies opt to do so


the life science sector’s support services of the future by leveraging the UK’s reputation for world leading HTA assessment